Factors associated with patients with RA missing some or all MTX doses in the last 4 weeks whose rheumatologist reported MTX use at the most recent registry visit (n = 228 patients). Values are mean (SD) unless otherwise specified.
| Variables | Missed 1 or More MTX Dose(s), n = 45 | Took all MTX Doses, n = 183 | p |
|---|---|---|---|
| Age, yrs | 51.96 (11.70) | 53.49 (12.61) | 0.46 |
| Female, n (%) | 38 (84.4) | 146 (79.8) | 0.47 |
| CDAI | 20.05 (15.92) | 16.82 (14.39) | 0.21 |
| mHAQ | 0.47 (0.50) | 0.40 (0.47) | 0.64 |
| PGA, 0–100 | 34.71 (26.31) | 27.36 (23.35) | 0.08 |
| PtGA, 0–100 | 45.53 (29.94) | 36.81 (25.86) | 0.06 |
| Patient pain, 0–100 | 43.82 (31.60) | 38.01 (27.06) | 0.29 |
| Disease duration, yrs | 9.05 (8.85) | 6.88 (8.23) | 0.22 |
| Glucocorticoid use, n (%) | 15 (33.3) | 44 (24.0) | 0.20 |
| Biologics, n (%) | 41 (91.1) | 173 (94.5) | 0.39 |
| MTX use, n (%) | 0.56 | ||
| Oral | 19 (73.1) | 143 (78.1) | |
| SQ | 7 (26.9) | 40 (21.9) |
RA: rheumatoid arthritis; MTX: methotrexate; CDAI: Clinical Disease Activity Index; mHAQ: modified Health Assessment Questionnaire; PGA: physician’s global assessment; PtGA: patient’s global assessment; SQ: subcutaneous.